RESUMEN
How would the European bio-based industrial landscape look now if the Bio-based Industries Joint Undertaking (BBI JU) had not been created? While we obviously cannot know this, today after almost seven years of operation following its creation in 2014, the BBI JU has certainly established a solid reputation for high impact delivery and is driving the systemic transformation of the EU bio-based sector. This article provides an overview of the most visible effects generated in the bio-based sector together with the principal achievements realised so far (2014-2019), using practical examples from BBI JU projects. The partnership is on track to out-perform almost all of its performance targets by the end of 2020, including the production of new bio-based materials and the creation of new value chains, and has launched nine flagship projects that see biorefineries operating at pre-commercial scale, the first of their kind in Europe. The main reasons behind the success of the initiative, including the added value of working as an institutionalised partnership, are discussed. Several factors are highlighted, including the dynamic alignment of the strategies of both the EU and industry, and the efficiency of the programming process, which is driven by the industry in close collaboration with the European Commission. Finally, the article discusses the relevance of the work already done with a view to a future initiative under Horizon Europe, in the context of the European Green Deal and the needs of future generations.
Asunto(s)
Biotecnología , Industria Farmacéutica , Preparaciones Farmacéuticas/química , Asociación entre el Sector Público-Privado , Europa (Continente)RESUMEN
This article discusses the preparation, structure and objectives of the Bio-based Industries Joint Undertaking (BBI JU). BBI JU is a public-private partnership (PPP) between the European Commission (EC) and the Bio-based Industries Consortium (BIC), the industry-led private not-for-profit organisation representing the private sectors across the bio-based industries. The model of the public-private partnership has been successful as a new approach to supporting research and innovation and de-risking investment in Europe. The BBI JU became a reality in 2014 and represents the largest industrial and economic cooperation endeavour financially ever undertaken in Europe in the area of industrial biotechnologies. It is considered to be one of the most forward-looking initiatives under Horizon 2020 and demonstrates the circular economy in action. The BBI JU will be the catalyst for this strategy to mobilise actors across Europe including large industry, small and medium-sized enterprises (SMEs), all types of research organisations, networks and universities. It will support regions and in doing so, the European Union Member States and associated countries in the implementation of their bioeconomy strategies.
Asunto(s)
Biotecnología , Conservación de los Recursos Naturales , Desarrollo Económico , Europa (Continente) , Modelos Económicos , Asociación entre el Sector Público-PrivadoAsunto(s)
Enfermedades Genéticas Congénitas , Pruebas Genéticas , Salud Pública , Enfermedades Genéticas Congénitas/diagnóstico , Enfermedades Genéticas Congénitas/genética , Pruebas Genéticas/economía , Pruebas Genéticas/ética , Pruebas Genéticas/legislación & jurisprudencia , Pruebas Genéticas/normas , Política de Salud , Humanos , Guías de Práctica Clínica como AsuntoAsunto(s)
Pruebas Genéticas/economía , Pruebas Genéticas/estadística & datos numéricos , Patentes como Asunto/legislación & jurisprudencia , Europa (Continente) , Unión Europea , Pruebas Genéticas/legislación & jurisprudencia , Humanos , Concesión de Licencias/economía , Concesión de Licencias/legislación & jurisprudencia , Sector PúblicoRESUMEN
The sharing of samples and data stored in biobanks for research has implications for donor privacy, but also raises questions on the regulation of research within Europe. Many legal documents and principles within Europe, with a direct impact on biobanking, have not been developed specifically to support this activity. Moreover, while some new regulations have been set up at national level, there are many variations in the definitions, scope and purpose of these legal instruments. This has resulted in unnecessary hurdles for genome-based research, particularly if samples are shared across national borders. The question is also raised on whether new, specific legislative and governance frameworks designed for biobanking are needed, or whether it is sufficient to modify current general law and to develop specific guidelines, or to accommodate issues raised by biobanking in the current regulation. A workshop with experts from academia and industry, lawyers, national data protection authorities, representatives from the European Commission and the European Data Protection Supervisor was held to review the existing legal bottlenecks and future needs of biobanking, with special regard to the collection, exchange and linkage of samples and data. This report presents highlights of the presentations and discussions from the workshop held in Sevilla, Spain, in March 2007 and the conclusions that followed. The workshop focused on the internal linkage of data and samples stored in a biobank, and the external linkage of biobanks with secondary information resources, such as cancer registries.
Asunto(s)
Bancos de Muestras Biológicas/legislación & jurisprudencia , Confidencialidad/legislación & jurisprudencia , Bases de Datos Genéticas/legislación & jurisprudencia , Investigación Genética/legislación & jurisprudencia , Bancos de Muestras Biológicas/ética , Bancos de Muestras Biológicas/tendencias , Confidencialidad/ética , Bases de Datos Genéticas/ética , Europa (Continente) , Investigación Genética/ética , Regulación GubernamentalRESUMEN
Preimplantation genetic diagnosis (PGD) is now well established and provided in many European countries. However, regulations, professional standards and accreditation requirements can differ notably. Furthermore, no comprehensive independent data exist either about practice and provision in Europe or about the quality assurance practices and procedures designed to optimize the quality of the results. Consequently, a study was launched to obtain knowledge, currently lacking, of the provision and quality assurance of PGD services and cross-border activities in Europe. An online questionnaire was developed and sent to PGD providers, and expert opinions were obtained through interviews with professionals in specific countries. Information was gathered from 53 centres offering PGD in 17 European countries. There is a diverse array of tests available, with a trend for custom-made services. Although half of the centres have a designated quality manager, just 33% have achieved or are preparing for accreditation or certification. About 66% of the centres responded that they did not participate in external quality assessment, a problem exacerbated by the lack of existing PGD-specific schemes. Approximately 19% of the centres do not keep data on accuracy and 9% do not even follow up until birth. PGD is an expanding activity with an increasing international flow that accounts for approximately one-third of the activity reported. The survey highlights a significant need for improvement in quality assurance in PGD centres. On the positive side, important improvements in the quality management of these services are expected with the European Tissue Directive entering into force.
Asunto(s)
Enfermedades Genéticas Congénitas/diagnóstico , Pruebas Genéticas/métodos , Diagnóstico Preimplantación , Europa (Continente) , Enfermedades Genéticas Congénitas/genética , HumanosRESUMEN
Eleni Zika is currently a research program manager at the Medical Research Council (London, UK). Previously she was a research fellow in the 'Agriculture and Life Sciences in the Economy' unit of the Institute for Prospective Technological Studies of the European Commission, where her work focused on the socioeconomic impacts of biotechnology, including pharmacogenetics. Prior to that, she worked as a Christine Mirzayan Science and Technology Policy Fellow at the US National Academies (Washington DC, USA), where she performed research on the role of intellectual property in research innovation, particularly as related to genomics and proteomics. She received her PhD in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill (NC, USA). Her graduate work focused on the regulation of immunity but also on the ethical, legal and social implications of genetics.
RESUMEN
Class II major histocompatibility (MHC-II) genes are prototype targets of IFN-gamma. IFN-gamma activates the expression of the non-DNA-binding master regulator of MHC-II, class II transactivator (CIITA), which is crucial for enhanceosome formation and gene activation. This report shows the importance of the histone methyltransferase, coactivator-associated arginine methyltransferase (CARM1/PRMT4), during IFN-gamma-induced MHC-II gene activation. It also demonstrates the coordinated regulation of CIITA, CARM1, and the acetyltransferase cyclic-AMP response element binding (CREB)-binding protein (CBP) during this process. CARM1 synergizes with CIITA in activating MHC-II transcription and synergy is abrogated when an arginine methyltransferase-defective CARM1 mutant is used. Protein-arginine methyltransferase 1 has much less effect on MHC-II transcription. Specific RNA interference reduced CARM1 expression as well as MHC-II expression. The recruitment of CARM1 to the promoter requires endogenous CIITA and results in methylation of histone H3-R17; hence, CIITA is an upstream regulator of histone methylation. Previous work has shown that CARM1 can methylate CBP at three arginine residues. Using wild-type CBP and a mutant of CBP lacking the CARM1-targeted arginine residues (R3A), we show that arginine methylation of CBP is required for IFN-gamma induction of MHC-II. A kinetic analysis shows that CIITA, CARM1, and H3-R17 methylation all precede CBP loading on the MHC-II promoter during IFN-gamma treatment. These results suggest functional and temporal relationships among CIITA, CARM1, and CBP for IFN-gamma induction of MHC-II.
Asunto(s)
Proteínas Portadoras/fisiología , Regulación de la Expresión Génica/efectos de los fármacos , Genes MHC Clase II , Interferón gamma/farmacología , Proteínas Nucleares/fisiología , Proteína-Arginina N-Metiltransferasas/fisiología , Transactivadores/fisiología , Animales , Línea Celular , Corticosterona , Antígenos HLA-DR/genética , Cadenas alfa de HLA-DR , Humanos , Metilación , Regiones Promotoras Genéticas , ARN Interferente Pequeño/farmacología , Transcripción Genética , Activación TranscripcionalRESUMEN
Eighteen human histone deacetylases (HDACs) have been identified, and according to their sequence similarity to yeast homologs, these enzymes are grouped into distinct classes. Within class II, HDAC4, HDAC5, HDAC7, and HDAC9 share similar domain organization both within the N-terminal extension and the C-terminal catalytic domain, thus forming a subclass known as class IIa. These HDACs function as signal-responsive transcriptional corepressors. To gain further insight into their function and regulation, we utilized an N-terminal fragment of HDAC4 as bait in yeast two-hybrid screens, which uncovered myocyte enhancer factor 2C, 14-3-3zeta, and ankyrin repeat family A protein (ANKRA). ANKRA is a poorly characterized protein with an ankyrin repeat domain similar to RFXANK, a subunit of the trimeric transcription factor RFX. Mutations on genes of the RFX subunits and the coactivator CIITA are responsible for the bare lymphocyte syndrome, an immunodeficiency disorder attributed to the lack of major histocompatibility complex class II (MHCII) antigens. Through its ankyrin repeat domain, RFXANK interacted with HDAC4. Two RFXANK-binding sites were found on HDAC4 with one located within residues 118-279 and another within residues 448-666. Interestingly, this deacetylase also interacted with CIITA. Consistent with the physical interaction with RFXANK and CIITA, HDAC4 and homologs repressed MHCII expression. These results identify ANKRA, RFXANK, and CIITA as novel targets of class IIa HDACs and suggest that these deacetylases play a role in regulating MHCII expression.
Asunto(s)
Ancirinas/química , Antígenos de Histocompatibilidad Clase II/metabolismo , Histona Desacetilasas/química , Glicoproteínas de Membrana/química , Factores de Transcripción/química , Proteínas 14-3-3/química , Animales , Ancirinas/metabolismo , Sitios de Unión , Línea Celular , Proteínas de Unión al ADN , Dimerización , Eliminación de Gen , Genes Reporteros , Proteínas Fluorescentes Verdes/metabolismo , Células HeLa , Humanos , Insectos , Proteínas de Dominio MADS , Factores de Transcripción MEF2 , Glicoproteínas de Membrana/metabolismo , Ratones , Microscopía Fluorescente , Modelos Genéticos , Mutación , Factores Reguladores Miogénicos/química , Células 3T3 NIH , Proteínas Nucleares/química , Plásmidos/metabolismo , Unión Proteica , Estructura Terciaria de Proteína , Proteínas Represoras/química , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Transactivadores/química , Factores de Transcripción/metabolismo , Técnicas del Sistema de Dos HíbridosRESUMEN
Recent advances have shown the crucial role of histone-modifying enzymes in controlling gene activation and repression. This led to the 'histone code' hypothesis, which proposes that combinations of histone modifications work in concert to affect specific gene expression. Mounting evidence suggests that the class II transactivator modulates promoter accessibility by coordinating the recruitment of chromatin modifiers in a time-dependent fashion. MHC-II expression is exquisitely controlled by these highly specific, coordinated and dynamic interactions at the promoter.
Asunto(s)
Epigénesis Genética , Genes MHC Clase II/genética , Histonas/inmunología , Proteínas Nucleares/genética , Transactivadores/genética , Animales , Ensamble y Desensamble de Cromatina/genética , Ensamble y Desensamble de Cromatina/inmunología , Epigénesis Genética/inmunología , Genes MHC Clase II/inmunología , Humanos , Proteínas Nucleares/inmunología , Regiones Promotoras Genéticas/genética , Regiones Promotoras Genéticas/inmunología , Transactivadores/inmunologíaRESUMEN
Although increasing evidence indicates that there is a direct link between ubiquitination and mono-ubiquitination and transcription in yeast, this link has not been demonstrated in higher eukaryotes. Here we show that the major histocompatibility complex (MHC) class II transactivator (CIITA), which is required for expression of genes encoding MHC class II molecules, is ubiquitinated. This ubiquitination enhanced the association of CIITA with both MHC class II transcription factors and the MHC class II promoter, resulting in an increase in transactivation function and in the expression of MHC class II mRNA. The degree of CIITA ubiquitination was controlled by histone acetylases (HATs) and deacetylases (HDACs), indicating that the crucial cellular processes mediated by these enzymes are linked to regulate transcription. Thus, ubiquitin positively regulates a mammalian coactivator by enhancing its assembly at the promoter.
Asunto(s)
Proteínas Nucleares , Transactivadores/metabolismo , Activación Transcripcional , Ubiquitina/metabolismo , Animales , Cromatina/metabolismo , Antígenos de Histocompatibilidad Clase II/biosíntesis , Antígenos de Histocompatibilidad Clase II/genética , Histona Desacetilasas/metabolismo , Humanos , Regiones Promotoras GenéticasRESUMEN
We show here that steroid receptor coactivator 1 (SRC-1) is a coactivator of MHC class II genes that stimulates their interferon gamma (IFNgamma) and class II transactivator (CIITA)-mediated expression. SRC-1 interacts physically with the N-terminal activation domain of CIITA through two regions: one central [extending from amino acids (aa) 360-839] that contains the nuclear receptors binding region and one C-terminal (aa 1138-1441) that contains the activation domain 2. Using chromatin immunoprecipitation assays we show that SRC-1 recruitment on the class II promoter is enhanced upon IFNgamma stimulation. Most importantly, SRC-1 relieves the inhibitory action of estrogens on the IFNgamma-mediated induction of class II genes in transient transfection assays. We provide evidence that inhibition by estradiol is due to multiple events such as slightly reduced recruitment of CIITA and SRC-1 and severely inhibited assembly of the preinitiation complex.
Asunto(s)
Interferón gamma/fisiología , Esteroides/fisiología , Factores de Transcripción/fisiología , Animales , Secuencia de Bases , Neoplasias de la Mama , Células COS , Línea Celular Tumoral , Chlorocebus aethiops , Cartilla de ADN , Genes MHC Clase II , Genes Reporteros , Células HeLa , Antígenos de Histocompatibilidad Clase II/inmunología , Histona Acetiltransferasas , Humanos , Luciferasas/genética , Ratones , Coactivador 1 de Receptor Nuclear , Reacción en Cadena de la Polimerasa , Regiones Promotoras Genéticas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Factores de Transcripción/genética , TransfecciónRESUMEN
The class II transactivator (CIITA) is a master transcriptional regulator of major histocompatibility complex class II (MHC-II) promoters. CIITA does not bind DNA, but it interacts with the transcription factors RFX5, NF-Y, and CREB and associated chromatin-modifying enzymes to form an enhanceosome. This report examines the effects of histone deacetylases 1 and 2 (HDAC1/HDAC2) on MHC-II gene induction by gamma interferon (IFN-gamma) and CIITA. The results show that an inhibitor of HDACs, trichostatin A, enhances IFN-gamma-induced MHC-II expression, while HDAC1/HDAC2 inhibits IFN-gamma- and CIITA-induced MHC-II gene expression. mSin3A, a corepressor of HDAC1/HDAC2, is important for this inhibition, while NcoR, a corepressor of HDAC3, is not. The effect of this inhibition is directed at CIITA, since HDAC1/HDAC2 reduces transactivation by a GAL4-CIITA fusion protein. CIITA binds to overexpressed and endogenous HDAC1, suggesting that HDAC and CIITA may affect each other by direct or indirect association. Inhibition of HDAC activity dramatically increases the association of NF-YB and RFX5 with CIITA, the assembly of CIITA, NF-YB, and RFX5 enhanceosome, and the extent of H3 acetylation at the MHC-II promoter. These results suggest a model where HDAC1/HDAC2 affect the function of CIITA through a disruption of MHC-II enhanceosome and relevant coactivator-transcription factor association and provide evidence that CIITA may act as a molecular switch to modulate MHC-II transcription by coordinating the functions of both histone acetylases and HDACs.